The Genetic Connection
The effectiveness of groundbreaking weight loss medications, such as those mimicking GLP-1 and GIP hormones, isn't uniform across all users. While some
individuals achieve significant weight reduction, reportedly losing over 25% of their body weight, others experience negligible changes, with some studies indicating an average loss of 10%. This disparity has led to scientific inquiry into the underlying causes. A notable study involving nearly 28,000 participants who were taking these weight loss drugs revealed a potential genetic link. Researchers identified a specific gene variant that influences how well the drug binds to its receptor. Individuals with one copy of this variant showed an average additional weight loss of 0.76 kilograms over eight months, while those with two copies experienced an even greater average additional loss of approximately 1.5 kilograms. Furthermore, this genetic marker was also associated with the intensity of side effects like nausea and vomiting, with one drug, tirzepatide, notably increasing the risk of vomiting.
Implications for India
For the Indian population, the insights from this genetic research are particularly significant. Experts suggest that variations in weight loss outcomes are indeed partly influenced by genetic factors. Previous studies on Indian populations have already indicated that specific gene variants, such as FTO and VDR, play a role in how individuals respond to dietary changes. Additionally, genes like Neurobeachin have been suggested to modulate weight loss patterns in those using GLP-1 based therapies. This latest study reinforces these observations with more substantial data. Given the diverse range of obesity types and the increasing use of these advanced weight loss drugs in India, further research is crucial. Well-designed studies focusing on Indian demographics are essential to ascertain whether genetic profiling can pave the way for personalized obesity management strategies, helping to identify which individuals are most likely to benefit from specific therapeutic approaches.
Varied Responses Observed
Leading diabetologists in India have been observing distinct responses among their patients undergoing treatment with weight loss medications, including earlier versions of GLP-1 agonists like liraglutide. They've categorized patient responses into four main groups: those experiencing optimal results with reductions in both HbA1c (a measure of average blood sugar over three months) and weight; a group showing better weight loss but less impact on HbA1c; another group primarily seeing a dip in HbA1c without significant weight reduction; and a smaller, more challenging group where neither weight nor HbA1c levels improved. These categories are often referred to as 'super responders,' 'partial responders,' and 'non-responders.' This phenomenon is deeply rooted in the field of pharmacogenomics, which examines how an individual's genetic makeup impacts their response to medications. By analyzing DNA, healthcare providers can potentially select the most effective drugs and optimal dosages, thereby maximizing benefits and minimizing adverse reactions. While current research on genetic links is still emerging, it's anticipated that future studies will reveal how drug efficacy is influenced by ethnicity, gender, age, and even specific sub-types of Type 2 diabetes, such as Insulin Resistant Obese Diabetes (IROD) versus insulin-deficient Type 2 diabetes.
